Is gnpx a good buy

**Genprex, Inc. (GNPX) does not appear to be a good buy at this time.** Here's why:

1. **Financial Performance**: The company has reported a net loss of $6.5 million for the quarter ending June 30, 2024, and a diluted EPS of -$0.03, indicating that the company is currently unprofitable.
2. **Revenue Growth**: The company has experienced a year-over-year revenue decline of -18.7%, which is a concern.
3. **Free Cash Flow and Debt**: The company has generated a negative free cash flow of $-6.14 million as of June 30, 2024, and the debt-to-equity ratio is not available. The negative free cash flow suggests that the company is not generating sufficient cash to cover its operating expenses.
4. **Technical Indicators**: The stock's technical indicators such as the 5-Day, 10-Day, and 50-Day moving averages are trending downwards, with the 50-Day moving average being the lowest at $0.66. The Relative Strength Index (RSI) is not available, but a downward trend in the moving averages could indicate a bearish sentiment.
5. **Support and Resistance Levels**: The current support level is at $0.66, and the resistance level is at $0.68. The stock is trading close to its support level, which could limit the stock's upside potential.
6. **Recent Developments**: Genprex has announced positive clinical study updates for its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer, which could have a positive impact on the company's future prospects.
7. **Market Sentiment**: There is no analyst coverage or price targets available for Genprex, which makes it difficult to gauge the market's expectations or sentiment towards the stock.

In conclusion, given the company's financial losses, revenue decline, negative free cash flow, high debt, and negative technical indicators, it is advisable to exercise caution. Investors should consider the company's clinical trial progress, regulatory compliance, and the achievability of analyst price targets before making an investment decision.